Table 1.
Summary of the RSV vaccines and monoclonal antibodies in clinical development by target population. Only the most advanced trial for a specific target group is reported. RSV: respiratory syncytial virus; NIAID: National Institute of Allergy and Infectious Diseases; mAb: monoclonal antibody.
| Target Population | Vaccine Name | Sponsor | Vaccine Type | Clinical Trial Phase |
|---|---|---|---|---|
| Pregnant women | ResVax | Novavax | Particle-based | III |
| RSV F DS-Cav1 VRC-RSVRGP084-00-VP |
NIAID | Subunit | I | |
| RSV vaccine | Pfizer | Subunit | II | |
| GSK3888550A | GlaxoSmithKline | Subunit | II | |
| Children | RSV F nanoparticle | Novavax | Particle-based | I |
| SynGEM | Mucosis | Particle-based | II | |
| Ad26.RSV.preF | Janssen | Vector-based | I/IIa | |
| ChAd155-RSV | GlaxoSmithKline | Vector-based | II | |
| MEDI-534 | MedImmune (AstraZeneca) | Vector-based | I | |
| SeVRSV | NIAID | Vector-based | I | |
| RSV MEDI ΔM2-2 | NIAID | Live-attenuated | I/II | |
| RSV LID ΔM2-2 | NIAID | Live-attenuated | I | |
| RSV cps2 | NIAID | Live-attenuated | I | |
| RSV LID cp ΔM2-2 | NIAID | Live-attenuated | I | |
| RSV LID ΔM2-2 1030s | NIAID | Live-attenuated | I | |
| RSV D46/NS2/N/ΔM2-2-HindIII | NIAID | Live-attenuated | I | |
| RSV ΔNS2 Δ1313 I1314L | NIAID | Live-attenuated | I | |
| RSV 6120/ΔNS1; RSV 6120/F1/G2/ΔNS1 |
NIAID | Live-attenuated | I | |
| RSV ΔNS2/Δ1313/I1314L; RSV 6120/ΔNS2/1030s; RSV 276 |
NIAID | Live-attenuated | I/II | |
| RSV 6120/∆NS2/1030s | NIAID | Live-attenuated | I | |
| RSV ΔNS2/Δ1313/I1314L; RSV 276 |
NIAID | Live-attenuated | I | |
| RSV D46 cpΔM2-2 | NIAID | Live-attenuated | I | |
| MEDI-559 | MedImmune (AstraZeneca) | Live-attenuated | I/II | |
| MV-012-968 | Meissa Vaccines | Live-attenuated | I | |
| rBCG-N-hRSV | Pontificia Universidad Catolica de Chile | Chimeric | I | |
| MEDI-8897 (nirsevimab) | MedImmune (AstraZeneca) | mAb | III | |
| MK-1654 | Merck Sharp and Dohme Corporation | mAb | IIa | |
| Elderly | RSV F nanoparticle | Novavax | Particle-based | III |
| SynGEM | Mucosis | Particle-based | II | |
| MVA-BN RSV | Bavarian Nordic | Vector-based | II | |
| VXA-RSVf oral | Vaxart | Vector-based | I | |
| Ad26.RSV.preF | Janssen | Vector-based | II | |
| PanAd3-RSV and MVA-RSV | ReiThera | Vector-based | I | |
| DPX-RSV | Dalhousie University | Subunit | I | |
| RSV vaccine | Pfizer | Subunit | II | |
| GSK3844766A | GlaxoSmithKline | Subunit | I |